Drug Guidance for Subsidy 06/02/2026 Donanemab and lecanemab for treating mild cognitive impairment and mild dementia due to Alzheimer’s disease NRDonanemab and lecanemab are not recommended for inclusion on the MOH List of Subsidised Drugs for ... See all × 06/02/2026 Donanemab and lecanemab for treating mild cognitive impairment and mild dementia due to Alzheimer’s disease NRDonanemab and lecanemab are not recommended for inclusion on the MOH List of Subsidised Drugs for treating mild cognitive impairment and mild dementia due to Alzheimer’s disease. NRThis is because the current available evidence shows that the treatment effects for donanemab and for lecanemab were small with uncertain clinical meaningfulness, and the short trial durations limited the understanding of the treatments’ impact over the full course of the disease. NRGiven the uncertainty in clinical benefit and significant additional healthcare resources required to assess treatment eligibility and risks, as well as for regular magnetic resonance imaging (MRI) monitoring, funding these drugs would not represent a cost-effective use of healthcare resources and could place undue strain on the healthcare system.
Post Marketing Information PEM 11/03/2025 lormalzi (donanemab): A Guide for Healthcare Professionals: Important Safety Information on Donanemab Treatment to Minimise Risk of Amyloid-Related Imaging Abnormalities (ARIA) PAC 11/03/2025 Patient Alert Card: Important Safety Information for patients taking Lormalzi® (donanemab)
INTRAVENOUS Select a brand starting with the letter: L LORMALZI CONCENTRATE FOR SOLUTION FOR INFUSION 350MG/20ML [SIN17201P]